Trials / Completed
CompletedNCT05115006
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
Adjuvant Melanoma Stakeholder Treatment Preference Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 294 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.
Conditions
Timeline
- Start date
- 2021-01-07
- Primary completion
- 2022-06-02
- Completion
- 2022-06-02
- First posted
- 2021-11-10
- Last updated
- 2022-06-30
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05115006. Inclusion in this directory is not an endorsement.